Member of the Federation Council, doctor Sergei Leonov described the characteristics of three Russian vaccines against coronavirus and spoke about their main differences. "The vaccine developed by the Vector Center, EpiVacCorona, is the mildest vaccine, it is artificially synthesized and will have fewer side effects," he said during a briefing at the Rossiya Segodnya news agency. Leonov noted that Sputnik V is a vaccine averaged in terms of activity, so the body reacts to it quite actively, including with an increase in temperature. "The most vigorous vaccine is the development of the Chumakov Center - KoviVak. It carries a large amount of antigens, the body's reaction to it will be more pronounced, and as a result, a more stable immunity is developed," the senator said. According to Leonov, "KoviVak" is best suited for young and middle-aged patients with good health, and "EpiVacCorona" will be preferable for the elderly in terms of the degree of impact on the body. The doctor noted that the Sputnik V vaccine may be suitable for different patients, depending on the indications of doctors. As noted by another senator, surgeon Yuri Arkharov, at present, Russian specialists continue to work on new vaccines against COVID-19. He said that today more than 20 types of vaccines are at the stage of development and preclinical research. Arkharov also said whether it is worth getting vaccinated for those who have already had an infection. According to him, in such cases it is necessary to obtain a doctor's testimony, which can be obtained if the amount of antibodies in the patient's body drops to the so-called "gray" zone. Large-scale vaccination started in Russia on January 18. Citizens of the country can be vaccinated with one of two drugs registered in the country - "Sputnik V" or "EpiVacCorona". The first vaccine was created at the Russian Gamaleya Center in August, and the second - at the Vector Center on October 27. The third Russian vaccine against COVID-19 developed by the Chumakov Center "KoviVac" should go into civil circulation in the near future, and its registration is scheduled for February 20.